127 related articles for article (PubMed ID: 16633061)
1. Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates.
Surowiak P; Materna V; Drag-Zalesinska M; Wojnar A; Kaplenko I; Spaczyński M; Dietel M; Zabel M; Lage H
Int J Gynecol Pathol; 2006 Apr; 25(2):131-9. PubMed ID: 16633061
[TBL] [Abstract][Full Text] [Related]
2. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer.
Bauerschlag DO; Habermann M; Weimer J; Meinhold-Heerlein I; Hilpert F; Weigel M; Bauer M; Mundhenke C; Jonat W; Maass N; Schem C
Anticancer Res; 2010 Jul; 30(7):2739-44. PubMed ID: 20683007
[TBL] [Abstract][Full Text] [Related]
4. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
[TBL] [Abstract][Full Text] [Related]
5. Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer.
Märkl B; Arnholdt HM; Jähnig H; Schenkirsch G; Herrmann RA; Haude K; Spatz H; Anthuber M; Schlimok G; Oruzio D
Hum Pathol; 2010 Jul; 41(7):1024-33. PubMed ID: 20334895
[TBL] [Abstract][Full Text] [Related]
6. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx.
Marioni G; Blandamura S; Giacomelli L; Calgaro N; Segato P; Leo G; Fischetto D; Staffieri A; de Filippis C
Histopathology; 2005 May; 46(5):576-82. PubMed ID: 15842640
[TBL] [Abstract][Full Text] [Related]
7. Expression of maspin in endometrioid adenocarcinoma of endometrium.
Li HW; Leung SW; Chan CS; Yu MM; Wong YF
Oncol Rep; 2007 Feb; 17(2):393-8. PubMed ID: 17203179
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of maspin expression in human ovarian carcinoma cells.
Rose SL; Fitzgerald MP; White NO; Hitchler MJ; Futscher BW; De Geest K; Domann FE
Gynecol Oncol; 2006 Aug; 102(2):319-24. PubMed ID: 16457875
[TBL] [Abstract][Full Text] [Related]
9. Nuclear maspin expression as a good prognostic factor in human epithelial ovarian carcinoma.
Sopel M; Surowiak P; Berdowska I
Folia Morphol (Warsz); 2010 Nov; 69(4):204-12. PubMed ID: 21120806
[TBL] [Abstract][Full Text] [Related]
10. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
Solomon LA; Munkarah AR; Schimp VL; Arabi MH; Morris RT; Nassar H; Ali-Fehmi R
Gynecol Oncol; 2006 Jun; 101(3):385-9. PubMed ID: 16443262
[TBL] [Abstract][Full Text] [Related]
11. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
12. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
13. Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients.
Klasa-Mazurkiewicz D; Narkiewicz J; Milczek T; Lipińska B; Emerich J
Gynecol Oncol; 2009 Apr; 113(1):91-8. PubMed ID: 19193429
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients.
Surowiak P; Materna V; Kłak K; Spaczyński M; Dietel M; Kristiansen G; Lage H; Zabel M
Pol J Pathol; 2005; 56(2):69-74. PubMed ID: 16092668
[TBL] [Abstract][Full Text] [Related]
15. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells.
O'Donnell JD; Linger RJ; Kruk PA
Gynecol Oncol; 2010 Feb; 116(2):262-8. PubMed ID: 19906413
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression.
Yu M; Zheng H; Tsuneyama K; Takahashi H; Nomoto K; Xu H; Takano Y
Hum Pathol; 2007 Aug; 38(8):1248-55. PubMed ID: 17490717
[TBL] [Abstract][Full Text] [Related]
18. MASPIN subcellular localization and expression in oral cavity squamous cell carcinoma.
Marioni G; Gaio E; Giacomelli L; Bertolin A; D'Alessandro E; Stramare R; Facco E; Staffieri A; Blandamura S
Eur Arch Otorhinolaryngol; 2008 Jul; 265 Suppl 1():S97-104. PubMed ID: 18236066
[TBL] [Abstract][Full Text] [Related]
19. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
Leong CT; Ong CK; Tay SK; Huynh H
Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
[TBL] [Abstract][Full Text] [Related]
20. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma.
Lonardo F; Li X; Siddiq F; Singh R; Al-Abbadi M; Pass HI; Sheng S
Lung Cancer; 2006 Jan; 51(1):31-9. PubMed ID: 16159682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
